Vitamin B-6 and B-1 Status during Hormone Therapy of Gynecological Cancer

  • H.-A. Ladner
  • R. M. Salkeld
Part of the Experimental Biology and Medicine book series (EBAM, volume 23)


The vitamin B-6 status (α-EGOT, PLP in erythrocytes) is impaired in patients with gynecological cancer (cervix uteri, endometrium, ovary and breast), mainly in patients with stage II and III uterine and ovarian carcinomas. We compared the occurrence of 3 important prognostic factors, undifferentiated malignant tumor patients with oestrogen-progesterone-poor receptor status, tumor grading, ploidy status and the epidermal growth factor (EGF) in these patients with the vitamin B-6 status before the beginning of therapy. We found that the low PLP values before treatment were also a prognostic factor for poor survival or the occurrence of distant metastases. Similar to our findings about the lack of influence of chemotherapy on vitamin B-6 and B-1 metabolism, we also found no changes in the vitamin B-6 and B-1 values, (EGOT, PLP and ETK) in 39 patients with gynecological carcinoma during hormone therapy. Only tumor progression caused the vitamin B-6 deficiency in these female tumor patients.


Epidermal Growth Factor Receptor Hormone Therapy Ovarian Carcinoma Gynecological Cancer Cervix Uterus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bauknecht T, Rau B, Meerpohl H, Pfleiderer A. The prognostic value of the presence of EGF receptors in ovarian carcinomas. Tumor Diagn Ther 1984; 5: 62–66.Google Scholar
  2. 2.
    Bauknecht T, Kiechle M, Bauer G, Siebers J. Characterization of growth factors in human ovarian carcinomas. Cancer Res 1986; 46: 2614–2618.Google Scholar
  3. 3.
    Bauknecht T, Runge M, Schwall M, Pfleiderer A. Occurrence of epidermal growth factor receptors (EGF-R) in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 1988; 29: 147–159.CrossRefGoogle Scholar
  4. 4.
    Bender DA. Oestrogens and vitamin B-6 actions and interactions. World Rev Nutr Diet 1987; 51: 140.Google Scholar
  5. 5.
    Bunce GE, Vessai M. Effect of zinc and/or pyridoxine deficiency upon oestrogen retention and oestrogen receptor distribution in the rat uterus. J Steroid Biochem 1987; 26: 303.CrossRefGoogle Scholar
  6. 6.
    Carpenter G, Cohen S. Epidermal growth factors. Ann Rev Biochem 1979; 48: 193–216.CrossRefGoogle Scholar
  7. 7.
    Creasman WT, Sasso RA, Weed JC, McCartey KS. Ovarian carcinoma: histologic and clinical correlation of cytoplastic estrogen and progesterone binding. Gynecol Oncol 1981; 12: 319–327.CrossRefGoogle Scholar
  8. 8.
    DeVita VT, Chabner BA, Livingston DM, Oliverio VT. Anergy and tryptophan metabolism in Hodgkin’s disease. Am J Clin Nutr 1971; 24: 835–840.Google Scholar
  9. 9.
    Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MNH. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984; 44: 397–400.Google Scholar
  10. 10.
    Ladner H-A, Lieser H. Zum Vitamin B-6-Stoffwechsel während der gynäkologischen Strahlentherapie. Radiologe 1972; 12: 240–242.Google Scholar
  11. 11.
    Ladner H-A, Salkeld RM. Vitamin B-6 status and administration during radiation therapy. In: Meyskens FL, jr, Prasad KN, eds. Vitamins and cancer. Clifton, New Jersey: Humana Press, 1986: 429–437.Google Scholar
  12. 12.
    Ladner H-A, Salkeld RM. Vitamin B-6 status in cancer patients: Effect of tumour site, irradiation, hormones and chemotherapy. In: Tryfiates GP, Prasad KN, eds. Nutrition, growth, and cancer. New York: Alan R Liss, 1988: 273–281.Google Scholar
  13. 13.
    Leklem JE, Brown RR, Potera C, Becker DS. A role for vitamin B-6 in cancer. In: Van Eys et al, eds. Nutrition and cancer. New York: SP Medical and Scientific Books, 1979.Google Scholar
  14. 14.
    Litwack G, Miller-Diener A, DiSorbo DM, Schmidt TJ. In: Reynolds RD, Leklem JE, eds. Vitamin B-6: its role in health and disease. New York: Alan R Liss, 1985: 177–191.Google Scholar
  15. 15.
    Pfleiderer A, Kleine W, König P, Geyer H. Hormonal receptors in endometrial cancer, analysis of clinical prognosis and risk factors. In: Wolff JP, Scott JS, eds. Hormones and sexual factors in human cancer aetiology. Amsterdam: Elsevier Science Publ BV, 1984: 35–46.Google Scholar
  16. 16.
    Perheentupa J, Lakshmanan J, Hoath SB, Fisher DA. Hormonal modulation of mouse plasma concentration of epidermal growth factor. Acta encocrinol 1987; 107: 571–576.Google Scholar
  17. 17.
    Potera C, Rose DP, Brown RR. Vitamin B-6 deficiency in cancer patients. Am J Clin Nutr 1977; 30: 1677–1679.Google Scholar
  18. 18.
    Quinn MA, Pearce P, Rome R, Funder JW, Fortune D, Pepperell RJ. Cytoplasmic steroid receptors in ovarian tumours. Brit J Obstet Gynecol 1982; 89: 754–759.CrossRefGoogle Scholar
  19. 19.
    Sainsbury J, Farndon J, Needham G, Malcolm A, Harris A. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987; I: 1398.Google Scholar
  20. 20.
    Schwartz PE, Livolsi VA, Hildreth N, MacLusky NJ, Naftolin FN, Eisenfeld AJ. Estrogen receptors in ovarian epithelial carcinoma. Obstet Gynecol 1982; 59: 229–238.Google Scholar
  21. 21.
    Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am J Clin Nutr 1987; 46: 659.Google Scholar
  22. 22.
    Vuilleumier JP, Keller HE, Rettenmaier R, Hunziker F. Clinical chemical methods for the routine assessment of the vitamin status in human populations. Part II: The water-soluble vitamins B-1, B-2 and B-6. Int J Vitam Nutr Res 1983; 53: 259–270.Google Scholar
  23. 23.
    Zetterberg A, Esparti PL. Prognostic significance of nuclear DNA levels in prostatic carcinoma. Scand J Urol Nephrol 1980; 55 (suppl): 53–59.Google Scholar

Copyright information

© The Humana Press Inc. 1990

Authors and Affiliations

  • H.-A. Ladner
    • 1
  • R. M. Salkeld
    • 2
  1. 1.Department of RadiologyUniversity Gynecology ClinicFreiburgFederal Republic of Germany
  2. 2.Section of Clinical Nutrition ResearchF. Hoffmann-La Roche LtdSwitzerland

Personalised recommendations